NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 26.72 against a street estimate of 22.82 — a beat of 17.1%.
with an average price target of ₹3,761.00.
CONFIDENT Strong Q1 FY27 start: 25% revenue growth, 31% PAT growth. India outperforming market; Africa branded surging 30%; Asia disrupted by geopolitical issues, expected recovery Q2+. Maintaining high-teens full-year guidance. Q1 FY27 India strong across therapies; Asia hit by Middle East geopolitical disruption (sales push to Q2); Africa robust branded growth and field expansion paying off; U.S. elevated but expected to normalize. Analysts pressed Asia recovery confidence (visibility soft), U.S. guidance credibility post-blockbuster Q1 (competitive pressures acknowledged), and India execution vs IPM data (IQVIA tracking issues blamed). Management deferred hard quantification, emphasizing qualitative visibility and maintaining disciplined guidance. 2026-07-30…
Full summary in the app.
| Document | Date |
|---|---|
| Q1 FY27 earnings call AJANTA PHARMA LIMITED – DOCUMENT SUMMARY HEADLINE INFORMATION • Document is a regulatory filing dated 3rd August 2026 disclosing an earnings call tr | 2026-08-03 |
| Annual report FY2026 AJANTA PHARMA LIMITED - ANNUAL REPORT FY 2025-26 SUMMARY HEADLINE NUMBERS • Revenue from operations: ₹5,453 cr. (grew 17% YoY from ₹4,648 cr.) • EBI | 2026-06-18 |
| Q4 FY26 earnings call AJANTA PHARMA LIMITED - DOCUMENT SUMMARY DOCUMENT STATUS • This is a regulatory filing dated 8th May 2026 submitting an earnings call transcript • Th | 2026-05-08 |
| Quarterly results · Q4 FY26 AJANTA PHARMA LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • FY 2026 Revenue: Rs. 5,453 crore, up 17% vs FY 2025 (Rs. 4,648 crore) • FY 2026 PAT: Rs | 2026-05-05 |
| Q3 FY26 earnings call AJANTA PHARMA LIMITED – DOCUMENT SUMMARY IMPORTANT NOTE This document is a regulatory filing letter only – it does NOT contain financial results, bus | 2026-02-05 |
| Quarterly results · Q3 FY26 AJANTA PHARMA LIMITED – FINANCIAL SUMMARY Q3 FY 2026 Results (Quarter & Nine Months Ended 31 December 2025) --- HEADLINE NUMBERS • Q3 FY 2026 Reven | 2026-01-30 |
| Q2 FY26 earnings call | 2025-11-06 |
| Quarterly results · Q2 FY26 AJANTA PHARMA LIMITED — FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 FY 2026 Revenue: Rs. 1,354 cr. (up 14% vs Q2 FY 2025: Rs. 1,187 cr.) • Q2 FY 2026 Pr | 2025-11-03 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹32 / share ex-date Aug 5, 2026 | 2026-08-05 |
| Dividend | ₹28 / share ex-date Nov 10, 2025 | 2025-11-10 |
| Announcement | Date |
|---|---|
| Interim dividend of Rs. 28 per equity share declared Ajanta Pharma's Board of Directors declared an interim dividend of Rs. 28 per equity share on November 3, 2025. This means shareholders will receive Rs. 28 for each share they own. Key Deta | 2025-11-03 |
| Interim dividend of 28 per equity share declared Ajanta Pharma Limited's Board of Directors declared an interim dividend of ₹28 per equity share on November 3, 2025. What happened: The company announced it will distribute cash to its shar | 2025-11-03 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Ajanta Pharma Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.